When does ropinirole hydrochloride’s patent expire?
Patent expiry depends on which specific patent family (and which country) applies to the ropinirole hydrochloride product being sold (including whether the reference product is the branded or an extended-release formulation). Patent timelines also can be affected by patent term adjustments, regulatory exclusivities, and any patent litigation that changes launch timing.
Because the exact drug strength/formulation (immediate-release vs extended-release) and the jurisdiction (for example, US vs EU vs UK vs India) aren’t specified, there isn’t enough provided information here to state a single definitive expiry date.
How do I find the exact expiry date for my country and formulation?
To get the correct “patent expiry” date for ropinirole hydrochloride, you typically need:
1) The reference product name and dosage form (e.g., immediate-release vs extended-release).
2) The jurisdiction (US, EU member states, UK, etc.).
3) The specific patent list tied to that product in that jurisdiction (often maintained by national patent or drug-registration/market-authorization authorities).
If you tell me the country and the formulation (immediate-release or extended-release), I can narrow down the right patent set to check and then summarize the expected earliest expiry/entry timing.
What other protections can delay generics even after “patent expiry”?
Even when the core patent expires, generic entry can still be delayed by:
- Regulatory exclusivities (where applicable)
- Additional later-expiring patents (method-of-use, formulation, polymorph, dosing regimen, etc.)
- Enforcement outcomes from patent disputes (which can include “automatic” delay mechanisms)
So “patent expiry” alone may not match the first day a generic actually launches.
Are there different patent expiries for immediate-release vs extended-release ropinirole?
Yes. Extended-release and formulation-specific patents can have different expiry dates than immediate-release products. Also, a given country may treat the reference product differently for approval and patent-linking purposes.
If you mean the US: what should I look up?
In the US, the usual approach is to look for patents listed for the reference product under the FDA’s patent listing framework and then identify the expiration dates of each listed patent. Launch timing for generics often depends on whether and when patents are cleared via litigation or other statutory mechanisms.
If you provide the US product name (and whether it’s immediate-release or extended-release), I can help you map which listed patents are typically the ones that control timing and what to check.
What to share so I can give you a concrete expiry date
Reply with:
- Country (e.g., US, UK, Germany, etc.)
- Product type (immediate-release or extended-release)
- Brand/reference product name if you know it
Then I can give a precise patent expiry answer for that specific ropinirole hydrochloride product.